Literature DB >> 11930326

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Stephen L Hoffman1, Lucy M L Goh, Thomas C Luke, Imogene Schneider, Thong P Le, Denise L Doolan, John Sacci, Patricia de la Vega, Megan Dowler, Chris Paul, Daniel M Gordon, Jose A Stoute, L W Preston Church, Martha Sedegah, D Gray Heppner, W Ripley Ballou, Thomas L Richie.   

Abstract

During 1989-1999, 11 volunteers were immunized by the bites of 1001-2927 irradiated mosquitoes harboring infectious sporozoites of Plasmodium falciparum (Pf) strain NF54 or clone 3D7/NF54. Ten volunteers were first challenged by the bites of Pf-infected mosquitoes 2-9 weeks after the last immunization, and all were protected. A volunteer challenged 10 weeks after the last immunization was not protected. Five previously protected volunteers were rechallenged 23-42 weeks after a secondary immunization, and 4 were protected. Two volunteers were protected when rechallenged with a heterologous Pf strain (7G8). In total, there was protection in 24 of 26 challenges. These results expand published findings demonstrating that immunization by exposure to thousands of mosquitoes carrying radiation-attenuated Pf sporozoites is safe and well tolerated and elicits strain-transcendent protective immunity that persists for at least 42 weeks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11930326     DOI: 10.1086/339409

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  290 in total

1.  Cures for the Third World's problems: the application of genomics to the diseases plaguing the developing world may have huge medical and economic benefits for those countries and might even prevent armed conflict.

Authors:  Samuel Broder; Stephen L Hoffman; Peter J Hotez
Journal:  EMBO Rep       Date:  2002-09       Impact factor: 8.807

2.  Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle.

Authors:  Myriam Bodescot; Olivier Silvie; Anthony Siau; Philippe Refour; Paco Pino; Jean-François Franetich; Laurent Hannoun; Robert Sauerwein; Dominique Mazier
Journal:  Parasitol Res       Date:  2004-02-12       Impact factor: 2.289

3.  Fighting malaria at the crossroads.

Authors:  Andrea Rinaldi
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

4.  GlaxoSmithKline malaria vaccine phase 3 trial heralded.

Authors:  Simon Franz
Journal:  Nat Biotechnol       Date:  2011-12-08       Impact factor: 54.908

Review 5.  Large screen approaches to identify novel malaria vaccine candidates.

Authors:  D Huw Davies; Patrick Duffy; Jean-Luc Bodmer; Philip L Felgner; Denise L Doolan
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

6.  Laser mimicking mosquito bites for skin delivery of malaria sporozoite vaccines.

Authors:  Chang Zhou; Xinyuan Chen; Qi Zhang; Ji Wang; Mei X Wu
Journal:  J Control Release       Date:  2015-02-25       Impact factor: 9.776

7.  CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii.

Authors:  Katherine L Doll; Noah S Butler; John T Harty
Journal:  Vaccine       Date:  2013-12-07       Impact factor: 3.641

8.  Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites.

Authors:  Olivia C Finney; Gladys J Keitany; Hannah Smithers; Alexis Kaushansky; Stefan Kappe; Ruobing Wang
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

Review 9.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.